157 related articles for article (PubMed ID: 35501995)
1. Targeting XPO1-Dependent Nuclear Export in Cancer.
Kim E; Mordovkina DA; Sorokin A
Biochemistry (Mosc); 2022 Jan; 87(Suppl 1):S178-S70. PubMed ID: 35501995
[TBL] [Abstract][Full Text] [Related]
2. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
[TBL] [Abstract][Full Text] [Related]
3. Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.
Taylor J; Sendino M; Gorelick AN; Pastore A; Chang MT; Penson AV; Gavrila EI; Stewart C; Melnik EM; Herrejon Chavez F; Bitner L; Yoshimi A; Lee SC; Inoue D; Liu B; Zhang XJ; Mato AR; Dogan A; Kharas MG; Chen Y; Wang D; Soni RK; Hendrickson RC; Prieto G; Rodriguez JA; Taylor BS; Abdel-Wahab O
Cancer Discov; 2019 Oct; 9(10):1452-1467. PubMed ID: 31285298
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC
Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282
[TBL] [Abstract][Full Text] [Related]
5. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
6. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
7. XPO1-dependent nuclear export as a target for cancer therapy.
Azizian NG; Li Y
J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
[TBL] [Abstract][Full Text] [Related]
8. Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
Totiger TM; Chaudhry S; Musi E; Afaghani J; Montoya S; Owusu-Ansah F; Lee S; Schwartz G; Klimek V; Taylor J
J Cell Mol Med; 2023 Feb; 27(4):587-590. PubMed ID: 36722323
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
10. The hippo kinase STK38 ensures functionality of XPO1.
Martin AP; Camonis JH
Cell Cycle; 2020 Nov; 19(22):2982-2995. PubMed ID: 33017560
[TBL] [Abstract][Full Text] [Related]
11. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
12. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
13. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Jardin F; Pujals A; Pelletier L; Bohers E; Camus V; Mareschal S; Dubois S; Sola B; Ochmann M; Lemonnier F; Viailly PJ; Bertrand P; Maingonnat C; Traverse-Glehen A; Gaulard P; Damotte D; Delarue R; Haioun C; Argueta C; Landesman Y; Salles G; Jais JP; Figeac M; Copie-Bergman C; Molina TJ; Picquenot JM; Cornic M; Fest T; Milpied N; Lemasle E; Stamatoullas A; Moeller P; Dyer MJ; Sundstrom C; Bastard C; Tilly H; Leroy K
Am J Hematol; 2016 Sep; 91(9):923-30. PubMed ID: 27312795
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
15. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
17. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
[TBL] [Abstract][Full Text] [Related]
18. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1.
Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY
Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695
[TBL] [Abstract][Full Text] [Related]
19. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
[TBL] [Abstract][Full Text] [Related]
20. Effects of exportin 1 on nuclear transport and meiotic resumption in porcine full-grown and growing oocytes.
Onuma A; Fujioka YA; Fujii W; Sugiura K; Naito K
Biol Reprod; 2018 Apr; 98(4):501-509. PubMed ID: 29228114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
